China Healthcare Stocks On Recovery Path After $142 Billion Rout
China’s Junshi Nabs FDA Approval in Rare Success for US Foray
Merck Discontinues Developing Drug Candidates With Sichuan Kelun After Daiichi Sankyo Deal
China Drug-Price Negotiations Offers Glimpse Into Future for Companies in US
